Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetics Generation AdvancementROCO:4160 -1.20%70 Interest Coverage is 21.38 as of Dec. 2025, which is 98% below its 10-year median of 1,244.22. GuruFocus rates ROCO:4160 with a GF Score™ of 70/100 and a GF Value™ of NT$51.35 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 93 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks better than 66.67% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Genetics Generation Advancement's
Operating Income
for the
three
months ended in Dec. 2025 was NT$8.1 Mil. Genetics Generation Advancement's Interest Expense for the
three
months ended in Dec. 2025 was NT$-0.4 Mil.
Genetics Generation Advancement's interest coverage for the quarter that ended in Dec. 2025 was 21.38.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Genetics Generation Advancement's Interest Coverage or its related term are showing as below:
ROCO:4160'
s Interest Coverage Range Over the Past 10 Years
Min: 20.03 Med: 1244.22 Max: No Debt
Current: 20.03
ROCO:4160's Interest Coverage is ranked better than 66.67% of 93
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.05
vs ROCO:4160: 20.03
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Genetics Generation Advancement Interest Coverage Related Terms
Genetics Generation Advancement Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ROCO:4160 vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement (ROCO:4160) has a Interest Coverage of 21.38 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genetics Generation Advancement and its competitors. This is 98% below median its historical median of 1,244.22. Over the past decade, Genetics Generation Advancement's Interest Coverage has ranged from 20.03 to 10,000.00. According to the industry distribution chart, Genetics Generation Advancement ranks #31 out of 93 companies in the Medical Diagnostics & Research industry, placing it in the top 33.3%.
Is Genetics Generation Advancement's Interest Coverage too high?
Genetics Generation Advancement's current Interest Coverage of 21.38 is 98% below median its 10-year median of 1,244.22. Over the past 10 years, this metric has ranged from a low of 20.03 to a high of 10,000.00. The Medical Diagnostics & Research industry median Interest Coverage is 9.05. Genetics Generation Advancement's value of 21.38 is 136.2% above this industry median. Based on the distribution chart, Genetics Generation Advancement ranks #31 out of 93 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #31 out of 93 companies for Interest Coverage. This puts Genetics Generation Advancement in the upper half of its industry. The industry median Interest Coverage is 9.05. Genetics Generation Advancement's value of 21.38 is 136.2% above this benchmark. Historically, Genetics Generation Advancement's own Interest Coverage has ranged from 20.03 to 10,000.00 over the past decade. While the company's 10-year median is 1,244.22 vs. the industry median of 9.05, Genetics Generation Advancement has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetics Generation Advancement's current Interest Coverage of 21.38 is 136.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genetics Generation Advancement and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current Interest Coverage is 21.38, which is 98% below median its own 10-year median of 1,244.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.35, compared to a current price of NT$41.15 — trading 19.9% below its estimated fair value. The current Interest Coverage is 21.38, which is 98% below median its 10-year median of 1,244.22 and 136.2% above the Medical Diagnostics & Research industry median of 9.05. Genetics Generation Advancement's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Interest Coverage is 21.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$41.15 is trading 19.9% below its estimated GF Value™ of NT$51.35.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
Interest Coverage: 21.38 (98% below median its 10-year median of 1,244.22)
GF Value™: NT$51.35 vs. price of NT$41.15 (19.9% below fair value)
Industry Position: 136.2% above the Medical Diagnostics & Research median (#31 of 93)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Business Description
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
70GF Score
Get the complete analysis for ROCO:4160
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
